Back to News
Market Impact: 0.2
Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM: VNDA) on September 23, 2026, with an Outperform recommendation. VNDA closed at $5.21 on September 22, ahead of the initiation; the article text does not provide a price target or subsequent market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
VNDA0.45
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- Meta's standoff with Amazon over Muse could be a sign of things to come
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow